We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-2.82%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.01B
AUM Growth
-$1.6B
Cap. Flow
-$1.27B
Cap. Flow %
-42.02%
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
23

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$89.8M
2
BDX icon
Becton Dickinson
BDX
+$70.5M
3
ZTS icon
Zoetis
ZTS
+$66.8M
4
MRK icon
Merck
MRK
+$64.8M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$60.5M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$218M
2
ARGX icon
argenx
ARGX
+$127M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$125M
4
BSX icon
Boston Scientific
BSX
+$113M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$100M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYT
76
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$3.21M 0.11%
1,764,100
-31,700
-2% -$51.5K
SYRS
77
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.42M 0.08%
904,630
+4,630
+0.5% +$17.9K
HYPR icon
78
Hyperfine
HYPR
$88.4M
$2.17M 0.07%
1,503,754
– –
CMAX
79
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$2.02M 0.07%
25,178
– –
BCAB icon
80
BioAtla
BCAB
$5.34M
$1.61M 0.05%
12,050
-13,150
-52% -$2.37M
ACIU icon
81
AC Immune
ACIU
$231M
$761K 0.03%
325,400
– –
REUN
82
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$104K ﹤0.01%
151,098
-409,202
-73% -$456K
NUVB.WS
83
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$12K ﹤0.01%
99,999
– –
AZN icon
84
AstraZeneca
AZN
$269B
– –
-600,000
Closed -$81.4M
BNTX icon
85
BioNTech
BNTX
$23.5B
– –
-215,400
Closed -$32.4M
DGX icon
86
Quest Diagnostics
DGX
$26B
– –
-258,000
Closed -$40.4M
EPIX
87
DELISTED
ESSA Pharma
EPIX
– –
-1,855,400
Closed -$4.68M
FATE icon
88
Fate Therapeutics
FATE
$275M
– –
-104,653
Closed -$1.06M
LLY icon
89
Eli Lilly
LLY
$1.08T
– –
-217,000
Closed -$79.4M
MDGL icon
90
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-430,000
Closed -$125M
OBIO icon
91
Orchestra BioMed
OBIO
$228M
– –
-400,000
Closed -$3.99M
SCYX icon
92
SCYNEXIS
SCYX
$37.4M
– –
-142,575
Closed -$1.78M
UTHR icon
93
United Therapeutics
UTHR
$26.1B
– –
-785,500
Closed -$218M
VRTX icon
94
Vertex Pharmaceuticals
VRTX
$123B
– –
-172,000
Closed -$49.7M
XBI icon
95
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-4,062,000
Closed -$337M
ZLAB icon
96
Zai Lab
ZLAB
$2.07B
– –
-31,309
Closed -$961K
LENZ
97
LENZ Therapeutics
LENZ
$179M
– –
-225,000
Closed -$5.23M
ITCI
98
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-504,000
Closed -$26.7M
ARYD
99
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
– –
-500,000
Closed -$5.05M
DCPH
100
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-1,126,000
Closed -$18.5M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2023 Portfolio in Review

As of Q1 2023, Avidity Partners Management held 106 positions worth $3.01B, down 35% from $4.62B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $1.27B in Q1 2023, closing 23 positions and reducing 41 holdings. Its most notable exit was United Therapeutics, an estimated $218M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $97.9M.

  • Avidity Partners Management's largest Q1 2023 buy was Regeneron Pharmaceuticals: 119,100 shares worth $97.9M.
  • Avidity Partners Management added most to Bio-Rad Laboratories Class A in Q1 2023, an estimated $60.5M increase.
  • Avidity Partners Management's biggest Q1 2023 reduction was argenx, cutting an estimated $127M.
  • Avidity Partners Management fully exited United Therapeutics in Q1 2023, selling an estimated $218M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2023.
  • Avidity Partners Management opened 21 new positions and closed 23 in Q1 2023.
  • Avidity Partners Management's portfolio value fell 35% quarter-over-quarter to $3.01B.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.